Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -50.9% | 2,187.3% | -95.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 99.9% | 99.3% | 97.6% | 2.3% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -73.8% | 19.9% | -1,845% | -76.5% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -90% | 11.3% | -2,004.4% | -127.2% |
| EPS Diluted | -0.04 | 0.009 | -0.07 | -0.09 |
| % Growth | -549.4% | 112.7% | 22.2% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |